AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21669557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimney woodstove intervention
Number of subjects: 119
Study 21669557 — intervention group
Group type: COMPARATOR
Intervention: Open fire use (control)
Number of subjects: 119
Study 19255287 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-PCT
Number of subjects: 82
Study 19255287 — intervention group
Group type: EXPERIMENTAL
Intervention: S-PCT
Number of subjects: 82
Study 19255287 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-PCT and S-PCT
Number of subjects: 82
Study 19255287 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-PCT/S-PCT ratio
Number of subjects: 82
Study 17822340 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine once daily
Number of subjects: 106
Study 17822340 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 106
Study 15017228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin
Number of subjects: 58
Study 15017228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11483141 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone treatment plus contingency management (CM)
Number of subjects: 127
Study 11483141 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone treatment, CM, plus significant other involvement (SO)
Number of subjects: 127
Study 11483141 — intervention group
Group type: EXPERIMENTAL
Intervention: significant other involvement (SO)
Number of subjects: 127
Study 11483141 — intervention group
Group type: COMPARATOR
Intervention: standard naltrexone treatment
Number of subjects: 127
Study 9740088 — intervention group
Group type: COMPARATOR
Intervention: MET + DEX (10 mg*4 and 2 mg*1, orally)
Number of subjects: 280
Study 9740088 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO (5 mg*1, orally)
Number of subjects: 280
Study 9740088 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO + MET (5 mg*1 and 10 mg*2, orally)
Number of subjects: 280
Study 9740088 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO + MET + DEX (5 mg*1, 10 mg*2, and 2 mg*1, orally)
Number of subjects: 280
Study 9740088 — intervention group
Group type: EXPERIMENTAL
Intervention: CHL + DEX (25 mg*2 and 2 mg*1, orally)
Number of subjects: 280
Study 9740088 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO + CHL (5 mg*1 and 12.5 mg*2, orally)
Number of subjects: 280
Study 9740088 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO + CHL + DEX (5 mg*1, 12.5 mg*2, and 2 mg*1, orally)
Number of subjects: 280
Study 7980668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice chips
Number of subjects: 39
Study 7980668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen cold air
Number of subjects: 39
Study 7980668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligno-paraffin
Number of subjects: 39
Study 7980668 — intervention group
Group type: COMPARATOR
Intervention: Placebo short wave diathermy
Number of subjects: 39
Study 2608537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% energy from fat)
Number of subjects: 0
Study 2608537 — intervention group
Group type: COMPARATOR
Intervention: Standard western diet (40% energy from fat)
Number of subjects: 0
Study 1126780 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylpsoralen
Number of subjects: 89
Study 1126780 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen
Number of subjects: 89
Study 1126780 — intervention group
Group type: COMPARATOR
Intervention: 8-methoxypsoralen
Number of subjects: 89
Study 30367952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz-tACS
Number of subjects: 22
Study 30367952 — intervention group
Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 22
Study 30367952 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 28797456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide gargle
Number of subjects: 60
Study 28797456 — intervention group
Group type: COMPARATOR
Intervention: Placebo gargle
Number of subjects: 60
Study 24856460 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI alone for localization of epilepsy related hemodynamic foci
Number of subjects: 26
Study 23717666 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 57
Study 20630604 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit instruction
Number of subjects: 20
Study 20630604 — intervention group
Group type: COMPARATOR
Intervention: Normal instruction
Number of subjects: 20
Study 18824499 — intervention group
Group type: EXPERIMENTAL
Intervention: NNBC-3 risk classification algorithm
Number of subjects: 410
Study 18824499 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant!
Number of subjects: 410
Study 18824499 — intervention group
Group type: COMPARATOR
Intervention: St Gallen risk classification
Number of subjects: 410
Study 16885182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg daily for 14 days)
Number of subjects: 902
Study 16885182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 902
Study 14687223 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + SDD (20 mg bid)
Number of subjects: 32
Study 14687223 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo (20 mg bid)
Number of subjects: 32
Study 14687223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 11757712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 2
Study 11757712 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 2
Study 11757712 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2
Study 9476468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine plus cisapride (5 mg)
Number of subjects: 8
Study 9476468 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch (14 mg/day)
Number of subjects: 8
Study 9476468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7958682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g of fish oil per day
Number of subjects: 60
Study 7958682 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.1 g of fish oil per day
Number of subjects: 60
Study 7958682 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.7 g of fish oil per day
Number of subjects: 60
Study 7958682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7958682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g of fish oil per day (in subsequent study with 15 patients)
Number of subjects: 60
Study 3665190 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-meat substitute (vegetable protein)
Number of subjects: 64
Study 3665190 — intervention group
Group type: COMPARATOR
Intervention: Meat substitute
Number of subjects: 64
Study 28589618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% twice daily for 2 weeks, then moisturizer cream twice daily for 2 weeks
Number of subjects: 30
Study 28589618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% twice daily for 2 weeks, then once daily for another 2 weeks
Number of subjects: 30
Study 28589618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% twice daily for 4 weeks
Number of subjects: 30
Study 28589618 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 27888594 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 dBA noise exposure for 20 minutes
Number of subjects: 100
Study 27888594 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed control group
Number of subjects: 100
Study 24662224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 34
Study 24662224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 34
Study 22343272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined counseling and disability evaluation
Number of subjects: 506
Study 22343272 — intervention group
Group type: COMPARATOR
Intervention: Disability evaluation
Number of subjects: 506
Study 20067513 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 80 mg alone
Number of subjects: 90
Study 20067513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg plus Ezetimibe 10 mg
Number of subjects: 90
Study 18753727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with amiodarone (100-200 mg/day) and enalapril (5 mg/day)
Number of subjects: 58
Study 18753727 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 58
Study 16299015 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 36567
Study 16299015 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 36567
Study 12207166 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized oil (200 mg iodine)
Number of subjects: 214
Study 10678693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant meanings of the target words
Number of subjects: 0
Study 10678693 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinate meanings of the target words
Number of subjects: 0
Study 10678693 — intervention group
Group type: COMPARATOR
Intervention: Contextual sentences (dominant or subordinate meaning)
Number of subjects: 0
Study 9105549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 1 g b.i.d. (median 7 days) in study A
Number of subjects: 74
Study 9105549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 2 g once daily (median 6 days) in study B
Number of subjects: 74
Study 7831435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 0
Study 7831435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3532749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 63
Study 3532749 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 63
Study 3532749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine + Hydrochlorothiazide
Number of subjects: 63
Study 29752907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 64
Study 29752907 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 64
Study 27782821 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF intervention and microscopy-based TB diagnostic algorithm in cohort A
Number of subjects: 10131
Study 27782821 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF intervention and Xpert-based TB diagnostic algorithm in cohort B
Number of subjects: 10131
Study 27782821 — intervention group
Group type: COMPARATOR
Intervention: Cohort R (retrospective cohort)
Number of subjects: 10131
Study 27782821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B (Xpert-based)
Number of subjects: 10131
Study 26281475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gamma-glutamyltransferase (GGT)
Number of subjects: 537
Study 26281475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting plasma glucose (FPG) and GGT
Number of subjects: 537
Study 26281475 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hr plasma glucose (2 hr PG)
Number of subjects: 537
Study 26281475 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 537
Study 26281475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GGT
Number of subjects: 537
Study 22085427 — intervention group
Group type: EXPERIMENTAL
Intervention: rmhTNF‐α plus standard chemotherapies
Number of subjects: 190
Study 22085427 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapies alone
Number of subjects: 190
Study 22085427 — intervention group
Group type: EXPERIMENTAL
Intervention: rmhTNF‐α plus standard chemotherapies (specifically in lung cancer)
Number of subjects: 190
Study 22085427 — intervention group
Group type: EXPERIMENTAL
Intervention: rmhTNF‐α
Number of subjects: 190
Study 22085427 — intervention group
Group type: COMPARATOR
Intervention: rmhTNF‐α plus standard chemotherapies vs standard chemotherapies alone
Number of subjects: 190
Study 20110397 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 8188
Study 18273633 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCranks
Number of subjects: 20
Study 18273633 — intervention group
Group type: COMPARATOR
Intervention: Conventional cranks
Number of subjects: 20
Study 15883432 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled and mashed orange-fleshed sweet potato (OFSP), 125 g daily for 53 school days, providing 1031 retinol activity equivalents/d as beta-carotene.
Number of subjects: 180
Study 15883432 — intervention group
Group type: COMPARATOR
Intervention: Control group consumed an equal amount of white-fleshed sweet potato devoid of beta-carotene for 53 school days.
Number of subjects: 180
Study 12522373 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 or 10 mg/kg
Number of subjects: 0
Study 12522373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11022632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education programme undertaken by 6 trained local women (nutrition advisers) in the SA.
Number of subjects: 1263
Study 8790023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (1, 2, 4, or 5 micrograms/min)
Number of subjects: 365
Study 8790023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (high doses)
Number of subjects: 365
Study 8790023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (highest dose)
Number of subjects: 365
Study 8790023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (all doses)
Number of subjects: 365
Study 8790023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban
Number of subjects: 365
Study 8790023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 31451419 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact precautions in a single-bed room
Number of subjects: 463
Study 31451419 — intervention group
Group type: COMPARATOR
Intervention: Contact precautions in a multiple-bed room
Number of subjects: 463
Study 30199881 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 1319
Study 30199881 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out plus
Number of subjects: 1319
Study 30199881 — intervention group
Group type: COMPARATOR
Intervention: Opt-out
Number of subjects: 1319
Study 27407053 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of extended-release niacin with 40 mg of laropiprant daily
Number of subjects: 25673
Study 27407053 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25673
Study 24703531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cetuximab
Number of subjects: 169
Study 24703531 — intervention group
Group type: COMPARATOR
Intervention: Continuous cetuximab
Number of subjects: 169
Study 22823075 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exercise (40-min submaximal incremental test followed by 90-min continuous exercise at 50% of maximal aerobic power-output and a 1-h rest period)
Number of subjects: 15
Study 22823075 — intervention group
Group type: COMPARATOR
Intervention: Light exercise (40-min submaximal incremental test followed by a 2.5-h rest period)
Number of subjects: 15
Study 18703165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004 articles reporting full CONSORT pre-randomization information
Number of subjects: 480
Study 18703165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2006 articles reporting full CONSORT pre-randomization information
Number of subjects: 480
Study 16313988 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriorvenous cerebral transit time (cTT)
Number of subjects: 30
Study 16313988 — intervention group
Group type: EXPERIMENTAL
Intervention: P3a latency
Number of subjects: 30
Study 14520516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (n = 6)
Number of subjects: 21
Study 14520516 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin (n = 6)
Number of subjects: 21
Study 14520516 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline (n = 9)
Number of subjects: 21
Study 11037739 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐isosorbide‐mononitrate (5‐ISMN) 30 mg three times daily for 7 days
Number of subjects: 11
Study 11037739 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of glyceryl trinitrate for 20 minutes
Number of subjects: 11
Study 9354191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-ASA 3 g/day
Number of subjects: 117
Study 9354191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 8247308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine Retard (40 mg twice a day)
Number of subjects: 36
Study 8247308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day)
Number of subjects: 36
Study 8247308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine Retard
Number of subjects: 36
Study 8247308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol + HCTZ 50 mg b.i.d.
Number of subjects: 22
Study 2880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + HCTZ 50 mg b.i.d.
Number of subjects: 22
Study 2880810 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 50 mg b.i.d. + placebo
Number of subjects: 22
Study 30286851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY) 5 mg
Number of subjects: 105
Study 30286851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 600 mg
Number of subjects: 105
Study 30286851 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) 500 mg
Number of subjects: 105
Study 30286851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY) 5 mg (Open CTR group)
Number of subjects: 105
Study 30286851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 600 mg (Open CTR group)
Number of subjects: 105
Study 30286851 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) 500 mg (Open CTR group)
Number of subjects: 105
Study 26813970 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glycan profiles determined by mass spectrometry in NSCLC cases
Number of subjects: 100
Study 26813970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination marker including serum glycan profiles
Number of subjects: 100
Study 26813970 — intervention group
Group type: EXPERIMENTAL
Intervention: Four glycan variables combined with pro-SFTPB
Number of subjects: 100
Study 24777164 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Rectal Evacuation (DE)
Number of subjects: 11
Study 24777164 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal Irrigation (TAI) with 500 ml
Number of subjects: 11
Study 24777164 — intervention group
Group type: EXPERIMENTAL
Intervention: Filling Cystometry (FC)
Number of subjects: 11
Study 22406126 — intervention group
Group type: EXPERIMENTAL
Intervention: Senofilcon A (ACUVUE® OASYS® with HYDRACLEAR® Plus) worn on a daily wear basis and replaced every 2 weeks
Number of subjects: 90
Study 20169196 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked condition (PD patients)
Number of subjects: 20
Study 20169196 — intervention group
Group type: COMPARATOR
Intervention: Blocked condition (Controls)
Number of subjects: 20
Study 20169196 — intervention group
Group type: EXPERIMENTAL
Intervention: Random condition (Both groups)
Number of subjects: 20
Study 18390450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (FDCs)
Number of subjects: 293
Study 18390450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (FDCs)
Number of subjects: 293
Study 18390450 — intervention group
Group type: COMPARATOR
Intervention: Group C (single drug formulations)
Number of subjects: 293
Study 16418753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=12)
Number of subjects: 30
Study 16418753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 30
Study 12740074 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize/soya‐based flour containing amylase
Number of subjects: 80
Study 12740074 — intervention group
Group type: COMPARATOR
Intervention: Maize/soya‐based flour without amylase (Control)
Number of subjects: 80
Study 10988131 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 30
Study 10988131 — intervention group
Group type: COMPARATOR
Intervention: Oxygen only (Control)
Number of subjects: 30
Study 8782022 — intervention group
Group type: EXPERIMENTAL
Intervention: Wooden backboard
Number of subjects: 37
Study 8782022 — intervention group
Group type: COMPARATOR
Intervention: Vacuum mattress-splint (VMS)
Number of subjects: 37
Study 1615966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh sperm
Number of subjects: 57
Study 1615966 — intervention group
Group type: COMPARATOR
Intervention: Frozen sperm
Number of subjects: 57
Study 1615966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh cervical cap insemination
Number of subjects: 57
Study 1615966 — intervention group
Group type: COMPARATOR
Intervention: Frozen cervical cap insemination
Number of subjects: 57
Study 1615966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh intrauterine insemination
Number of subjects: 57
Study 1615966 — intervention group
Group type: COMPARATOR
Intervention: Frozen intrauterine insemination
Number of subjects: 57
Study 6547101 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Nurse (single dose)
Number of subjects: 0
Study 6547101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29031239 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium animalis subsp. lactis BB‐12 and Lactobacillus rhamnosus GG)
Number of subjects: 60
Study 29031239 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo lozenges)
Number of subjects: 60
Study 27708111 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg
Number of subjects: 716
Study 27708111 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg plus ASA
Number of subjects: 716
Study 23602325 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 500
Study 23602325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupressure wristbands
Number of subjects: 500